Annual Securities Report — FY2025
What Nano Holdings,Inc. reported for the period from 2025-04-01 to 2026-03-31. Filed by ＮＡＮＯホールディングス株式会社
Filed 2026-06-26View the original on EDINET
How much it says
66Detailed
What moved here
28named for the first time
Its own wording
48terms
Which filing this is
33/ 33newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
On 1 April 2026, the company transitioned to a holding company structure through an incorporation-type company split and transferred the drug discovery business to newly established NANO MRNA Co., Ltd. During the consolidated fiscal year, the company also acquired shares in Luna RD Co., Ltd. as part of the NANO MRNA business. The filing describes progress in clinical development, including the planned submission of the clinical trial notification for the Phase Ib trial of TUG1 ASO.
Komori's summary of this document, not the document's own words.66Detailed
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
93
Very detailed
77
Very detailed
100
Very detailed
75
Very detailed
15
Almost nothing
68
Detailed
55
Typical
69
Detailed
53
Typical
35
Thin
50
Typical
R&D spend5億円Money spent making new things.
Cash left over14億円Cash from the business, less what went into equipment.
Spent on equipment20百万円Plants, machines — things meant to last.
Employees23Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.